CD8A and neoplasm: The combination treatment of DNMTi and histone deacetylase inhibitor (HDACi) is found to activate dsRNA which is sensed by MDA5 in ovarian cancer cells, thus exerting anti-tumor immunity affection via recruiting CD8 T and NK cells (27).